Metabolomics Market Size, Share, Trends And Forecast 2023-2028


(MENAFN- IMARC Group) The latest report by IMARC Group, titled“ Metabolomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 “, The global metabolomics market size reached US$ 2.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.7 Billion by 2028, exhibiting a growth rate (CAGR) of 11.55% during 2023-2028.

Factors Affecting the Growth of Metabolomics Industry:

  • Significant Technological Advancements in Metabolomics Instrumentation:

One of the primary driving forces behind the growth of the metabolomics market is the continuous advancement in technology, particularly in metabolomics instrumentation. This includes innovations in mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, and chromatography techniques, which are essential for metabolite identification and quantification. Mass spectrometry (MS) has witnessed significant advancements in resolution, sensitivity, and throughput, enabling researchers to analyze complex biological samples with greater accuracy and speed. New ionization techniques and instrumentation designs have enhanced the detection of metabolites even at trace levels, thereby expanding the scope of metabolomics research.

  • Rising Demand for Personalized Medicine and Precision Healthcare:

Another significant factor fueling the growth of the metabolomics market is the increasing demand for personalized medicine and precision healthcare. Metabolomics plays a crucial role in understanding individual variations in metabolic profiles, which can influence disease susceptibility, drug response, and overall health outcomes. By analyzing metabolic phenotypes, researchers and clinicians can identify biomarkers associated with specific diseases, allowing for early detection, accurate diagnosis, and targeted interventions. Metabolomics-based biomarker discovery holds immense potential in various medical fields, including oncology, cardiology, neurology, and metabolic disorders. Moreover, metabolomics enables pharmacometabolomic studies to personalize drug therapies based on the metabolic profile of an individual, optimizing treatment efficacy while minimizing adverse reactions. This approach is particularly beneficial in oncology, where drug metabolism and response can vary widely among patients, necessitating tailored treatment strategies.

  • Expansion of Metabolomics Applications Across Diverse Research Areas:

The versatility of metabolomics applications across diverse research areas is another key driver of market growth. Metabolomics has transcended traditional boundaries and found applications in various fields, including drug discovery and development, agriculture, environmental science, and nutraceuticals. In drug discovery, metabolomics enables the identification of novel drug targets, characterization of drug mechanisms of action, and evaluation of drug safety and efficacy. By providing insights into the metabolic changes induced by drug candidates, metabolomics accelerates the drug development process, reducing costs and failures in clinical trials. In agriculture, metabolomics contributes to crop improvement efforts by elucidating metabolic pathways related to stress tolerance, nutrient utilization, and product quality. Metabolomics-based approaches help breeders develop resilient and high-yielding crop varieties tailored to specific environmental conditions, ultimately enhancing food security and sustainability.

Competitive Landscape with Key Player:

  • Agilent Technologies Inc.
  • Biocrates Life Sciences AG
  • Bio-Rad Laboratories Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Human Metabolome Technologies Inc.
  • Metabolon Inc.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

For an in-depth analysis, you can refer sample copy of the report:
https://www.imarcgroup.com/metabolomics-market/requestsample

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Product:

  • Metabolomics Instruments
  • Metabolomics Bioinformatics Tools and Services

Metabolomics bioinformatics tools and services hold maximum number of shares due to the essential role they play in processing, analyzing, and interpreting the vast amounts of data generated from metabolomics experiments, enabling researchers to derive meaningful insights and advance their scientific discoveries.

Breakup by Indication:

  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Inborn Errors of Metabolism
  • Others

Cancer dominates the market due to the pressing need for early detection, accurate diagnosis, and personalized treatment strategies, which are facilitated by metabolomics-based biomarker discovery and therapeutic monitoring in oncology.

Breakup by Application:

  • Biomarker and Drug Discovery
  • Toxicology
  • Nutrigenomics
  • Personalized Medicine
  • Others

Biomarker and drug discovery represents the largest segment due to the critical role biomarkers play in disease diagnosis, prognosis, and treatment selection, driving demand for metabolomics technologies in precision medicine and clinical research.

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

North America's dominance in the metabolomics market is attributed to factors such as extensive research and development activities, well-established healthcare infrastructure, and high adoption rates of advanced metabolomics technologies in pharmaceutical and biotechnology industries.

Global Metabolomics Market Trends:

The rising demand for sustainable farming practices and the need to enhance crop productivity amidst changing climatic conditions are driving the adoption of metabolomics technologies in agriculture. Metabolomics enables the precise monitoring of plant metabolic pathways, facilitating the development of crop varieties with improved yield, nutritional value, and resilience to environmental stressors. Additionally, with growing awareness about the impact of diet on health and wellness, there is a rising interest in personalized nutrition strategies tailored to individual metabolic profiles. Metabolomics plays a pivotal role in identifying biomarkers related to dietary intake, metabolism, and nutritional status, enabling personalized dietary recommendations and the development of functional foods targeted at specific health outcomes.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email:

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

MENAFN24022024004122016232ID1107893273


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.